TARGET RESEARCH ARTICLES
-
Does TSLP Inhibition Signal The Next Wave Of Respiratory Biologics?
Thymic stromal lymphopoietin (TSLP) inhibition has firmly established itself as a strategy in respiratory disease. This article highlights some promising drug candidates and next-generation approaches.
-
The Missing Data Set In Drug Discovery: Patient Experience As Decision Data
Drug discovery has become highly effective at capturing molecular detail, yet the experience of disease remains difficult to incorporate into early scientific decisions.
-
What's Next For ADCs: How Combinations Will Help Define The Future Of Treatment
Insights gained from advancing ADC combination therapies in lung cancer are now shaping innovative approaches across multiple tumor types.
-
Rethinking Tau Biology: The Future Of Neurodegenerative Drug Discovery
We caught up with Melissa Murray, Ph.D., and Amy Rommel, Ph.D., to discuss tau-associated neurodegenerative diseases.
-
Proteomics Biomarkers Beyond Blood
Effective biomarker strategies have the potential to accelerate decision-making, de-risk development, and help drive precision medicine.
-
The Advantages Of Antibodies Over Ligands In The Alpha Emitter Era
The alpha era in radiopharmaceuticals is still being defined. The choices developers make now about delivery platforms will shape individual programs and the trajectory of the field.
TARGET RESEARCH ARTICLES. APP NOTES, CASE STUDIES. & WHITE PAPERS
-
New advances in chemomics, proteome mapping, and modern synthetic methods are redefining how quickly and precisely discovery teams can move from raw data to meaningful clinical momentum.
-
Sensitive digital PCR methods enable confident detection of low‑abundance iPSC markers. Gain insight into how these capabilities support more reliable monitoring and quality assessment.
-
Next generation sequencing technologies and workflow automation are accelerating genomic research. Learn key differences between sequencing methods and uncover strategies to boost efficiency.
-
A scalable bioreactor process enables efficient expansion of cord blood-derived HSCs and NK cell differentiation, delivering high purity and strong cytotoxicity, advancing immune cell therapies.
-
Metabolic pathways define immune cell roles, from glycolysis fueling inflammation to fatty acid oxidation sustaining memory and tolerance. Discover how energy metabolism shapes immune responses.
-
Explore how digital PCR technologies offer precise, reproducible AAV quantification to address qPCR limitations with streamlined workflows and dedicated CGT assays to support safe, consistent gene therapy development.
TARGET RESEARCH SOLUTIONS
-
High‑throughput scNMT‑seq offers a powerful way to map methylation and transcriptional activity. Learn about strategies that cut variability and support dependable multi‑omics datasets.
-
Generate human-relevant data with an Organ-Chip system that combines automation, imaging, and cost efficiency for faster, more confident insights for drug development and complex biological studies.
-
With 12 independent Emulations in one consumable, Chip-Array optimizes workflows and reduces cell requirements—delivering scalable, physiologically relevant models for advanced research.
-
From cancer models to high-throughput screening, Organ-Chip platforms accelerate development, improve safety, and support regulatory compliance for next-generation therapies.
-
Achieve precise cytokine and chemokine quantitation with flexible immunoassay solutions, including multiplexed bead-based assays, ELISA kits, and ELISPOT reagents, for human, rat, and mouse studies.
-
Our comprehensive off-target gene editing assessment platform integrates screening, nomination, and confirmation assays, providing unmatched precision in guide RNA selection and off-target risk assessment. By addressing safety and regulatory expectations early, our platform reduces development risks, streamlines therapeutic design, and accelerates your path to the clinic with confidence and efficiency.